USFDA plant clearances delayed
Bengaluru and Malaysia facilities have pending USFDA inspections; delays could impact Aspart, Bevacizumab, and other biosimilar launches in the US.
BIOCON / Q2-FY25 / risks
Keep the risk register visible.
Biocon · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Generics pricing pressure persists
Continued pricing pressure in the US generics market has impacted margins; recovery depends on cost improvements and new launches.
Humira biosimilar market share growth slow
Despite market share gains, Humira biosimilar adoption has been slower than expected; pricing competition may limit upside.
High net debt and capex outflows
Consolidated net debt increased to $1.4 billion despite refinancing; high capex (~₹900 crore in H1) may pressure free cash flow.